NRSN
Neurosense Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.62
−14.80%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.91
From 52W high−89.54%
Volume111899.00
Market cap$4.96M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.91
From 52W high
−89.54%
Volume
111899.00
Market cap
$4.96M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
21.7
MomentumView details →
1D Return
−14.80%
YTD Return
−84.40%
SummaryUpdated Dec 1, 2025
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) is a clinical-stage biotechnology company founded in 2017 and headquartered in Herzliya, Israel. The company went public in December 2021 and focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense is currently advancing its lead drug candidate through clinical trials while building a pipeline of potential treatments for some of the most challenging neurological conditions affecting millions of patients worldwide.
Similar companies
Latest newsMore news →
NeuroSense Therapeutics filed a U.S. patent application seeking protection for PrimeC use in traumatic brain injury, including concussion, blast-related brain injury and chronic traumatic encephalopathy.9h agoNeuroSense Therapeutics Ltd. said it has secured a NASDAQ, INC. hearing date, with its shares continuing to trade pending the Panel’s decision.6d agoNeuroSense Therapeutics announced a redesigned, capital-efficient development strategy for its ALS drug PrimeC, including an AI-enabled formulation characterization, a comparative study against edaravone, and an optimized Phase 3 PARAGON trial design, with a New Drug Submission to Health Canada targeted for December 2026.46d ago